X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The study showed that a) Rivelin patch was formulated with therapeutic anti-TNFα antibody fragments, b) those fragments were successfully delivered directly to inflamed mucosal tissue, and c) that the antibodies maintained a neutralizing effect on inflammatory cells.
Lead Product(s): Anti-TNFα Antibody
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
In this Phase 2 study investigating Rivelin-CLO across more than 20 clinical trial sites, a 20-µg dose resulted in a clinically significant reduction in OLP ulcer size, improvements in symptoms and quality of life, and a favorable safety profile compared to placebo.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Immunology Product Name: Rivelin-CLO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol to treat symptomatic Oral Lichen Planus (OLP) lesions. First study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Immunology Product Name: Rivelin-CLO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
Study conducted in OLP patients with the 20?g dose of Rivelin-CLO demonstrated a statistically significant improvement in ulcer area, and continued to show improvement through the end of 4 weeks.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
